Financial statements Eurofins Biopharma Product Testing Poland
Balance sheet of Eurofins Biopharma Product Testing Poland
Company age:
Age:
3 y. 3 m. 21 d.
Share capital:
Share capital:
5 000 PLN
Balance sheet data of EUROFINS BIOPHARMA PRODUCT TESTING POLAND
|
Year
|
2022
|
|---|---|
| Total assets | 70 078,46 |
| A. Fixed assets | 3 338,59 |
| B. Current assets | 66 739,87 |
| C. Share capital contributions (basic funds) | 0,00 |
| D. Own shares (stocks) | 0,00 |
| Total liabilities | 70 078,46 |
| A. Equity | -26 312,73 |
| B. Liabilities and provisions for liabilities | 96 391,19 |
| I. Long-term liabilities | 0,00 |
| II. Short-term liabilities | 73 527,17 |
Financial data is automatically retrieved from the EKRS webpage of the Ministry of Justice.
- Fixed Assets - Assets held for a longer period, typically longer than a year, such as real estate or machinery.
- Current Assets - Assets intended to be used or sold within a year, such as inventory, receivables, and cash.
- Equity - The net value of a company's assets, representing the difference between its assets and liabilities.
- Long-Term Liabilities - Financial obligations to be repaid over a period longer than a year, such as loans or bonds.
- Short-Term Liabilities - Financial obligations to be repaid within a year, such as payables to suppliers or short-term loans.
- Reserve Capital - A portion of equity set aside for specific purposes, such as covering losses or business development.